A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

NCT03763877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Fatty Liver

Interventions

DRUG: PXL770
DRUG: Placebo Oral Capsule

Sponsor

Poxel SA